{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:57:16Z","timestamp":1790927836654,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Testing and Analysis"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The gastric\u2010emptying and satiety effects of semaglutide may lead to its misuse by athletes in weight\u2010class sports, especially as the approved oral formulation is more convenient than subcutaneous injections. This study aimed to establish a simple ultrahigh\u2010performance liquid chromatography\u2010high resolution mass spectrometry (UHPLC\u2010HRMS) method for monitoring semaglutide abuse based on urinary metabolites U6 and U7, and elucidate the urinary excretion profile of the oral formulation. Multidimensional optimization determined three key factors for reliable trace detection (recovery &gt;\u200990%), with enhanced hydrophobic interactions dominating the enrichment process: (i) the adsorbent, (ii) the loading pH, and (iii) the washing solvent. Orbitrap\u2010HRMS operating in dual acquisition modes enabled both specific identification and retrospective analysis. Systematic qualitative and quantitative validation was performed, and a single oral microdose of semaglutide (3\u2009mg) was administered to a healthy volunteer, followed by continuous urine collection for 1\u2009week. The optimized method provided satisfactory sensitivity (limit of detection of 0.03\u2009ng\/mL) and quantitative performance (linearity range: 0.1\u201320\u2009ng\/mL,\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    \u2009&gt;\u20090.995; accuracy &gt;\u200985%) for both U6 and U7. Excretion profiling of 25 postdose samples showed that U6 and U7 were first detectable at 21\u2009h, peaked at 0.15 and 0.10\u2009ng\/mL, respectively, and remained detectable for up to 28\u2009h. Additionally, five abundant metabolites of the absorption enhancer salcaprozate sodium were identified (detection window up to 7\u2009days), serving as sensitive screening indicators for oral semaglutide. These findings demonstrate the effectiveness of the developed method and provide the first perspective on the urinary excretion profile of oral semaglutide.\n                  <\/jats:p>","DOI":"10.1002\/dta.70160","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:44:33Z","timestamp":1790927073000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Detection and Excretion Profiling of Semaglutide Use in Human Urine by UHPLC\u2010HRMS for Anti\u2010Doping Purpose"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6410-5974","authenticated-orcid":false,"given":"Tian","family":"Tian","sequence":"first","affiliation":[{"name":"Shanghai Anti\u2010Doping Laboratory Shanghai University of Sport  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[{"name":"Shanghai Anti\u2010Doping Laboratory Shanghai University of Sport  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1051-2507","authenticated-orcid":false,"given":"Xiaojun","family":"Deng","sequence":"additional","affiliation":[{"name":"Shanghai Anti\u2010Doping Laboratory Shanghai University of Sport  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"issue":"9548","key":"e_1_2_8_2_1","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The Incretin System: Glucagon\u2010Like Peptide\u20101 Receptor Agonists and Dipeptidyl Peptidase\u20104 Inhibitors in Type 2 Diabetes","volume":"368","author":"Drucker D. J.","year":"2006","journal-title":"Lancet"},{"issue":"1","key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/JS9.0000000000003450","article-title":"The Different Colorectal Tumor Risk Related to GLP\u20101 Receptor Agonists and SGLT2 Inhibitors Use: A Network Meta\u2010Analysis of 68 Randomized Controlled Trials","volume":"112","author":"Hung C. M.","year":"2026","journal-title":"International Journal of Surgery"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2026.114705","article-title":"Molecular Engineering of Designer Diabetes Therapeutics","volume":"392","author":"DeWolf E. L.","year":"2026","journal-title":"Journal of Controlled Release"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102298","article-title":"Long\u2010Acting GIPR Agonist LY3537021 Reduces Body Weight and Fasting Blood Glucose in Patients With T2D: Preclinical Development and Phase 1 Randomized Ascending Dose Studies","volume":"103","author":"Roell W.","year":"2026","journal-title":"Molecular Metabolism"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejps.2017.03.020","article-title":"Absorption, Metabolism and Excretion of the GLP\u20101 Analogue Semaglutide in Humans and Nonclinical Species","volume":"104","author":"Jensen L.","year":"2017","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"12","key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s40262-018-0649-2","article-title":"Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Renal Impairment","volume":"57","author":"Granhall C.","year":"2018","journal-title":"Clinical Pharmacokinetics"},{"issue":"18","key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the Once\u2010Weekly Glucagon\u2010Like Peptide\u20101 (GLP\u20101) Analogue Semaglutide","volume":"58","author":"Lau J.","year":"2015","journal-title":"Journal of Medicinal Chemistry"},{"issue":"4","key":"e_1_2_8_9_1","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.72144","article-title":"Evaluating the Efficacy, Safety, and Practical Considerations of Semaglutide for Weight Loss in Non\u2010Diabetic Adults: A Narrative Review","volume":"9","author":"Laraib A.","year":"2026","journal-title":"Health Science Reports"},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.disamonth.2026.102113","article-title":"Approved Weight Loss Drugs for Obesity With a Thorough Emphasis on GLP\u20101 Agonist Medications: A Systematic Review","volume":"102113","author":"Gunasekaran P.","year":"2026","journal-title":"Disease\u2010a\u2010Month"},{"issue":"3","key":"e_1_2_8_11_1","article-title":"Semaglutide\u2010Associated Acute Pancreatitis in a Patient With Type 2 Diabetes Mellitus: A Case Report","volume":"18","author":"Puri P.","year":"2026","journal-title":"Cureus"},{"issue":"1","key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.51821\/89.1.14613","article-title":"GLP\u20101 Receptor Agonist\u2010Associated Eosinophilic Duodenitis Presenting as a Bowel Obstruction: A Case Report and Literature Review","volume":"89","author":"Davidts S.","year":"2026","journal-title":"Acta Gastroenterologica Belgica"},{"issue":"12","key":"e_1_2_8_13_1","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf356","article-title":"From Weight Loss to Muscle Loss: Rhabdomyolysis Linked to Semaglutide","volume":"18","author":"Jadvani R.","year":"2025","journal-title":"Clinical Kidney Journal"},{"key":"e_1_2_8_14_1","unstructured":"World Anti\u2010Doping Agency \u201cThe 2024 Monitoring Program \u201d2024 https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/2023\u201009\/2024_list_monitoring_program_en_final_22_september_2023.pdf."},{"key":"e_1_2_8_15_1","unstructured":"World Anti\u2010Doping Agency \u201cThe 2026 Monitoring Program \u201d2026 https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/2025\u201009\/2026_list_monitoring_program_en_final_clean_september_2025.pdf."},{"issue":"3","key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/dta.70018","article-title":"Investigations Into the Human Metabolism of Trestolone (7alpha\u2010Methyl\u201019\u2010Nortestosterone)","volume":"18","author":"Piper T.","year":"2026","journal-title":"Drug Testing and Analysis"},{"issue":"12","key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1002\/dta.3953","article-title":"Clostebol Metabolism by Different Routes of Administration: Selection of Diagnostic Urinary Markers","volume":"17","author":"Torre X.","year":"2025","journal-title":"Drug Testing and Analysis"},{"issue":"45","key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"25158","DOI":"10.1021\/acs.analchem.5c04272","article-title":"A Computational Integration Strategy Driven by Chemical Similarity Uncovers Comprehensive Metabolic Profiles of Small Bioactive Peptides via UHPLC\u2010HRMS for Doping Control","volume":"97","author":"Tian T.","year":"2025","journal-title":"Analytical Chemistry"},{"issue":"28","key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1007\/s00216-024-05555-8","article-title":"Metabolic Profile Characterization of Voxelotor in Human Urine Based on In\u00a0Vivo and In\u00a0Vitro Models for Doping Control","volume":"416","author":"Liang X.","year":"2024","journal-title":"Analytical and Bioanalytical Chemistry"},{"issue":"4","key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00216-025-06263-7","article-title":"Identification of Semaglutide Use Through Detection of U6 and U7 Metabolites in Human Urine","volume":"418","author":"Timms M.","year":"2026","journal-title":"Analytical and Bioanalytical Chemistry"},{"issue":"6","key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40262-018-0728-4","article-title":"Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP\u20101 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects With Type 2 Diabetes","volume":"58","author":"Granhall C.","year":"2019","journal-title":"Clinical Pharmacokinetics"},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.2147\/DDDT.S166765","article-title":"The Development of an Oral GLP\u20101 Receptor Agonist for the Management of Type 2 Diabetes: Evidence to Date","volume":"13","author":"Antza C.","year":"2019","journal-title":"Drug Design, Development and Therapy"},{"issue":"17","key":"e_1_2_8_23_1","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13175166","article-title":"Efficacy and Safety in a Real\u2010World Study of the New Oral Formulation of Semaglutide in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus","volume":"13","author":"Marques Vidas M.","year":"2024","journal-title":"Journal of Clinical Medicine"},{"issue":"2","key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40262-020-00951-6","article-title":"Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus","volume":"60","author":"Clements J. N.","year":"2021","journal-title":"Clinical Pharmacokinetics"},{"issue":"4","key":"e_1_2_8_25_1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40262-025-01615-z","article-title":"Systemic Pharmacokinetic Principles of Therapeutic Peptides","volume":"65","author":"Nordell P.","year":"2026","journal-title":"Clinical Pharmacokinetics"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106895","article-title":"Absorption, Distribution, Metabolism, and Excretion of Tirzepatide in Humans, Rats, and Monkeys","volume":"202","author":"Martin J. A.","year":"2024","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"e_1_2_8_27_1","unstructured":"World Anti\u2010Doping Agency \u201cWADA Technical Document TD2023IDCR. Identification Criteria for Qualitative Assays \u201d (2023) https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/2023\u201002\/td2023idcrv1.1_eng_final.pdf."},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1007\/s00216-026-06478-2","article-title":"Comprehensive Metabolic Characterization of GBT1118 in Humans Using a Combined Approach via UHPLC\u2010HRMS for Doping Control","volume":"418","author":"Jing J.","year":"2026","journal-title":"Analytical and Bioanalytical Chemistry"},{"issue":"5","key":"e_1_2_8_29_1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/cpdd.938","article-title":"Relationship Between Oral Semaglutide Tablet Erosion and Pharmacokinetics: A Pharmacoscintigraphic Study","volume":"10","author":"Baekdal T. A.","year":"2021","journal-title":"Clinical Pharmacology in Drug Development"},{"issue":"1","key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13346-021-01000-w","article-title":"Development and Approval of Rybelsus (Oral Semaglutide): Ushering in a New Era in Peptide Delivery","volume":"12","author":"Lewis A. L.","year":"2022","journal-title":"Drug Delivery and Translational Research"},{"issue":"4","key":"e_1_2_8_31_1","article-title":"A Review of the Oral Semaglutide in Adults With Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity","volume":"18","author":"Ojinna B. T.","year":"2026","journal-title":"Cureus"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.70160","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dta.70160","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.70160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:44:37Z","timestamp":1790927077000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.70160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":30,"alternative-id":["10.1002\/dta.70160"],"URL":"https:\/\/doi.org\/10.1002\/dta.70160","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"2026-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"dta.70160"}}